Meta-analysis effects of levosimendan on mortality and hemodynamics in patients with sepsis  

作　　者：ZHAO Ming-rui ZHENG Rui YANG Yuan-zheng 

机构地区：[1]Emergency and Trauma College,Hainan Medical University,Haikou 571199,China

出　　处：《Journal of Hainan Medical University》2023年第13期50-57,共8页海南医学院学报（英文版）

基　　金：This study was supported by National Natural Foundation Project of China(No81760341)。

摘　　要：Objective:To investigate the effect of levosimendan on 28-day mortality in patients with sepsis.Methods:The English databases including Embase,PubMed,Web of Science,Cochrane Library and Chinese databasesincluding China National Knowledge Infrastructure(NKI),Wan fang Data,VIP,CBM were searched with levosimendan,sepsis and septic shock is as search terms.The published clinical randomized controlled trials of levosimendan injection were searched and the primary outcome measures of 28-day and 30-day mortality were included.Secondary outcome measures were left ventricular ejection fraction,left ventricular work index,cardiac index,and lactic acid.The literature retrieved is from the establishment of the database to October 2022.Stata 14.0 software was used for all data consolidation,publication bias monitoring and sensitivity analysis.Results:A total of 15 studies with 1337 patients were included in this meta-analysis.The results showed that at the 28-day mortality of patients with sepsis in the levosimendan group was not statistically superior to the 28-day mortality in the control group[RR=0.91,95%CI(0.78~1.06),Z=1.24,P=0.22].However,levosimendan can increase left ventricular ejection fraction,decrease left ventricular function index,increase cardiac index and decrease lactic acid in patients with sepsis.Conclusion:There is insufficient evidence to support a reduction in 28-day mortality in sepsis patients with levosimendan.However,levosimendan showed positive results on hemodynamic parameters,and more clinical trials are needed to verify the application of levosimendan in hemodynamic parameters of sepsis.

关 键 词：SEPSIS Septic shock LEVOSIMENDAN META-ANALYSIS 

分 类 号：R54[医药卫生—心血管疾病]